Integrating China into global precision medicine clinical development
Discover how an asset-specific approach can help determine whether, when, and how to integrate China into a global precision medicine program.
China’s role in precision medicine development is not simply a question of market or population size. Its value depends on the specific asset, biomarker-defined patient opportunity, and ability to execute within the global clinical development pathway.
Download our framework to explore how to assess China’s development value and execution readiness, from population science and biomarker prevalence to assay readiness, patient identification, site and laboratory capabilities, and regulatory dependencies.
Complete the form to download the white paper